Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology,
Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
February 2026—At the USCAP 2026 meeting, two guidelines on gastrointestinal pathology biomarkers will be presented. The updated guideline on HER2 testing in gastroesophageal adenocarcinoma reaffirms IHC with follow-up ISH as the best method for …
February 2026—The 2025 accreditation checklist edition, released December 9, includes revisions to address the use of digital pathology platforms in laboratories.
January 2026—Based on the results of Destiny-PanTumor02,1 targeted HER2-based therapies are now available as treatment options agnostic of tumor type. As oncologists seek to offer these targeted therapies to the patients likely to benefit, many laboratories have had to determine how best to expand the use of existing HER2 assays. At the same time, other laboratories may now see testing volumes increasing to justify new validation.
September 2025—The largest repository of pathology slides and tissue blocks is becoming a powerful data repository with the promise to transform diagnosis and treatment through the use of artificial intelligence. When U.S. military operations of all kinds were slashed or shuttered in 2008 under the Base Realignment and Closure federal initiative, a massive U.S. Army repository of slides and tissue blocks—including gross specimens dating back to the Civil War—came close to being one of the victims. It was housed at the Armed Forces Institute of Pathology, which had been targeted for closure. “When BRAC happened, and all of these Department of Defense facilities were closed, they didn’t know what to do with their pathology tissues,” says Mark D. Lyman, MD, Colonel, Medical Corps, U.S. Air Force, and director of the Joint Pathology Center (JPC), Silver Spring, Md. “There was even some discussion about throwing the repository away.”
October 2025—Glass or digital, onsite or remote—and what the rules are for the latter. That’s what Compass Group lab leaders talked about with CAP TODAY publisher Bob McGonnagle when they met online on Sept. 2. Here’s a glimpse into their digital pathology journeys. The Compass Group is an organization of not-for-profit IDN system laboratory leaders who collaborate to identify and share best practices and strategies.
October 2025—CAP Publications has released its newest book, Forensic Pathology: Principles and Pitfalls. It comes more than 20 years after the second edition of the CAP Handbook of Forensic Pathology was published. The book’s more than 900 pages comprise 36 chapters written by 57 contributors. CAP TODAY asked the following questions of the editors—Joseph Prahlow, MD, and Erin Brooks, MD—who led the publication of the comprehensive update.
September 2025—The largest repository of pathology slides and tissue blocks is becoming a powerful data repository with the promise to transform diagnosis and treatment through the use of artificial intelligence.
September 2025—In a CAP session last year on timely topics in thyroid tumors, Zubair W. Baloch, MD, PhD, shed light on poorly differentiated and differentiated high-grade follicular-derived carcinomas. “This is something new in the WHO 5th edition of the thyroid tumor classification scheme, and I think it’s about time that we have a different category and not really split them too much,” said Dr. Baloch, an editor and author of the 5th edition of the WHO Classification of Endocrine and Neuroendocrine Tumors. Why the category is new and what to know was part of the timely topics session, for which he paired up with Nikolina Dioufa, MD, PhD, MSc, who spoke about noninvasive follicular thyroid neoplasm with papillary-like nuclear features and follicular variant of papillary thyroid carcinoma.
August 2025—The noninvasive follicular thyroid neoplasm with papillary-like nuclear features, or NIFTP, is an entity that was introduced nearly a decade ago. It’s a lesion no longer considered malignant and instead grouped with more indolent lesions, owing to its observed indolent clinical behavior.
August 2025—Detection of extrachromosomal DNA in a tumor was found in a study published late last year to be associated with tumor stage, more prevalent after targeted and cytotoxic therapy, and associated with metastases and shorter overall survival.
